FDA Brief

FDA warning letters

A warning letter is FDA's formal notice that a company broke the law, usually found during an inspection. The company has 15 working days to reply. Letters that go unanswered lead to seizures, import bans or court orders.

3,819 letters. Newest first.

  1. Vivot LLC

    FDA warns Vivot LLC it lacked required foreign supplier food-safety checks for imported matcha and green tea.

    Medium
  2. Imu-Tek Animal Health, Incorporated

    FDA warns Imu-Tek Animal Health over unapproved drug claims and manufacturing failures for Colostrom-5 products.

    High risk
  3. Jubilant HollisterStier General Partnership

    FDA found sterile drug manufacturing and investigation failures at Jubilant HollisterStier in Kirkland.

    High risk
  4. Pamex Foods Incorporated

    Pamex Foods, a Maryland importer, had no FSVP records for three imported foods and never registered its facility.

    High risk
  5. Global Imports Origins

    FDA warns Global Imports Origins of Houston, TX, for lacking a foreign supplier verification program for imported Red Pepper.

    Medium
  6. Great Enterprise - Group - Inc.

    FDA says Great Enterprise Group, a Honolulu food importer, had no Foreign Supplier Verification Program for sauces, bamboo shoots and rice sticks.

    High risk
  7. NativeMed LLC dba NativeMed

    FDA warned telehealth seller NativeMed that its website misbranded compounded semaglutide and tirzepatide with false or misleading claims.

    Low
  8. HydraMed IV LLC dba HydraMed

    FDA told Denver telehealth seller HydraMed its website misbrands compounded semaglutide and tirzepatide with false or misleading claims.

    Low
  9. Nexus Health Solutions LLC dba Harper Meds

    FDA warned telehealth seller Harper Meds that its website misbrands compounded semaglutide and tirzepatide with false and misleading claims.

    Low
  10. FitRX, LLC dba AM RX

    FDA warned telehealth seller AM RX that its website misbrands compounded semaglutide and tirzepatide with false and misleading claims.

    Medium
  11. Altru Telehealth, LLC dba Altru Telehealth

    FDA warns Altru Telehealth that its website falsely claimed compounded semaglutide/tirzepatide and compounding pharmacies were FDA-approved.

    Low
  12. Eden Health International Inc. dba Eden

    FDA warned Eden Health International that its telehealth website misbrands compounded semaglutide and tirzepatide with false or misleading claims.

    Low
  13. Trinity HealthCare Supply, LLC dba altRx

    FDA warns altRx over misleading website claims for compounded semaglutide and tirzepatide, including 'clinically proven' and wrong compounder label.

    Low
  14. YS Group Inc.

    YS Group Inc. of Arcadia, CA, imported tofu skin, dried seaweed and buckwheat flour without any FSVP, FDA says.

    Medium
  15. Amie Health, Inc. dba Amie

    FDA warned telehealth seller Amie Health that its website misbrands compounded semaglutide and tirzepatide with false and misleading claims.

    Medium
  16. Thrivelab Co. dba Thrivelab

    FDA warned telehealth seller Thrivelab that its website misbrands compounded semaglutide with false claims suggesting FDA approval.

    Medium
  17. VivioMD Group LLC dba VivioMD

    FDA warned VivioMD that its website misbrands compounded semaglutide and tirzepatide by implying VivioMD is the compounder.

    Low
  18. Glow Medispa, LLC dba Mint Med

    FDA warns telehealth seller Mint Med that its website labels falsely suggest it compounds the semaglutide and tirzepatide drugs it sells.

    Low
  19. Nexlife Inc. dba Nexlife

    FDA warned Nexlife that its website labels for compounded semaglutide and tirzepatide falsely suggest Nexlife is the compounder.

    Low
  20. Public Health Solution LLC dba DrMedHealth

    FDA warned DrMedHealth over false website claims that compounded semaglutide and tirzepatide have the same active ingredient as Ozempic and Mounjaro.

    Low
  21. D&H Medical Services

    FDA warned D&H Medical Services that its website falsely suggests its compounded semaglutide and tirzepatide are the same as FDA-approved brand drugs.

    Low
  22. Momentum Health 360 dba Momentum Health

    FDA warned Momentum Health over false claims for compounded semaglutide, tirzepatide, and liraglutide.

    Low
  23. Medica Weight Loss

    FDA warns telehealth seller Medica Weight Loss that its compounded semaglutide and tirzepatide web claims are false and misbrand the drugs.

    Medium
  24. Ezra Holdco LLC dba Ezra

    FDA says Ezra's website misbrands compounded semaglutide and tirzepatide by labeling them as Ezra-made when they are not.

    Low
  25. Ready Med

    FDA warned Ready Med over website claims that compounded semaglutide and tirzepatide products were FDA-approved or FDA-licensed.

    Low
  26. FITISH

    FDA warned FITISH over misleading website claims for compounded semaglutide and tirzepatide, including labels suggesting it is the compounder.

    Low
  27. OrderlyMeds LLC dba OrderlyMeds

    FDA warned OrderlyMeds over website claims for compounded semaglutide and tirzepatide, saying its labels and 'FDA-licensed pharmacy' claim are misleading.

    Low
  28. Roen Health, Inc. dba RoenRx

    FDA warned RoenRx that its website misbrands compounded semaglutide with misleading approval claims and a company label implying it makes the drug.

    Medium
  29. Joi and Blokes dba Joi + Blokes

    FDA warned telehealth seller Joi + Blokes that its website misbrands compounded semaglutide and tirzepatide with false, misleading claims.

    Medium
  30. Nova Vascular LLC dba NOVARX

    FDA warned NOVARX over false website claims that compounded semaglutide and tirzepatide products are FDA-approved or from FDA-approved pharmacies.

    Low
  31. Clover Meds LLC dba Clover Meds

    Clover Meds, a telehealth seller, misbranded compounded semaglutide and tirzepatide with false website claims that it makes the drugs and uses 'FDA-licensed' facilities.

    Medium
  32. Maximus Health, Inc. dba Maximus

    FDA warned Maximus Health that its website makes false or misleading claims about compounded semaglutide and tirzepatide.

    Low
  33. Sante Manufacturing Inc.

    Sante Manufacturing’s OTC drugs have significant CGMP violations, including missing identity testing for a high-risk component and inadequate process validation and quality oversight.

    High risk
  34. InvaDerm, Inc.

    FDA says InvaDerm, Inc. of Somerset, NJ, markets unapproved new drugs without FDA-approved applications.

    High risk
  35. SL Follen Company

    FDA says SL Follen Company lacked required foreign supplier verification for imported fresh pineapple.

    Medium
  36. M G R Produce LLC

    FDA warns Houston produce importer M G R Produce for lacking an FSVP for imported scallions, jicama, and jalapenos.

    Medium
  37. Pharmathen International S.A.

    FDA warns Pharmathen over inadequate aseptic controls at its Greek plant making sterile drugs for the U.S.

    High risk
  38. ZOLL Medical Corporation

    FDA warned ZOLL Medical after an inspection found quality-system, design-validation, supplier, and reporting failures for defibrillators, ventilators, and electrodes.

    High risk
  39. Happiest Baby, Inc.

    FDA says Happiest Baby marketed unapproved SNOO sleep sacks and hospital bundle and mishandled complaints.

    High risk
  40. Hubei Gedian Humanwell Pharmaceutical Co., Ltd.

    FDA: Hubei Gedian Humanwell API plant has scratched, stained equipment and weak quality unit oversight.

    High risk
  41. Gopaldas Visram & Co., Ltd.

    FDA warns Indian OTC drug maker Gopaldas Visram over talc asbestos testing and data integrity failures.

    High risk
  42. Laboratorios Dr. Collado S.A.

    FDA warns Laboratorios Dr. Collado over inadequate asbestos testing and quality oversight for talc-containing over-the-counter drugs.

    High risk
  43. Revlon Group Holdings, LLC

    FDA cited Revlon's Oxford, NC over-the-counter drug plant for failing to test talc for asbestos and weak quality oversight.

    High risk
  44. Umendra Life Sciences Private Limited

    Umendra Life Sciences, an Indian maker of OTC talc-containing drugs, failed CGMP on talc testing and asbestos control, FDA says.

    High risk
  45. Erkul Kozmetik Sanayi ve Ticaret A.S.

    Erkul Kozmetik failed to test talc in OTC drugs for identity and asbestos, violating manufacturing rules.

    High risk
  46. PLZ Corp

    FDA warned PLZ Corp over an OTC talc drug made in Mississauga without asbestos testing and with deficient component controls.

    High risk
  47. Asanuma Corporation - Sagamihara Factory

    FDA warned Japan's Asanuma Sagamihara factory, an OTC drug maker, that its talc was never tested for asbestos.

    High risk
  48. Shantou Qiwei Industry Co., LTD

    FDA warns Shantou Qiwei, a Chinese OTC drug maker, that it never tested talc for asbestos, making its products adulterated.

    High risk
  49. Zydus Lifesciences Limited

    FDA warns Zydus Lifesciences over untested asbestos in talc used in its prescription drugs and altered lab data at its Himachal Pradesh plant.

    High risk
  50. Macau-Union Pharmaceutical Limited

    Macau-Union Pharmaceutical failed CGMP and sold unapproved, misbranded Bamboo Pharmacy OTC pain rubs in the U.S.

    High risk